Takeda wants to work with Chinese partners to bring China innovation global
In the next decade, Japan’s largest drugmaker Takeda Pharma (TYO: 4502) is hoping to bring more Chinese developed drugs to the global market by working with local partners in some key therapeutic areas, said its leaders at Takeda R&D China innovation forum held in Shanghai.
“Takeda wants to unleash the full potential of China’s market and we will do three things to achieve that,” said Takeda China president Sean Shan.
One is that Takeda plans to build computer power to find digital solutions for patients in China. The Tokyo-based pharma is already exploring such solutions in Japan. For example, it is developing a digital twin technology for patients with Crohn’s disease. This technology aims to simulate multiple treatment options on the digital model made from data of an individual patient and predict prognosis of each option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze